82 FR 47753 - Government-Owned Inventions; Availability for Licensing
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 197 (October 13, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 197 (October 13, 2017)
| Page Range | 47753-47754 | |
| FR Document | 2017-22146 |
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)] [Notices] [Pages 47753-47754] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-22146] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. A description of the technology follows. Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 [[Page 47754]] polyunsaturated fatty acid accumulates in the brain during development, and has been implicated in learning and memory development. DEA, a metabolite derived from DHA, also has been shown to accelerate neuronal growth and development. In vitro studies in which neural progenitor cells were treated with DEA derivatives showed an increase in the number of somatic neurons produced after differentiation. Potential Commercial ApplicationsNeurogenesis, Neurite growth, Synaptogenesis, Therapeutics for traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Inventors: Erika Englund (NCATS), Juan Marugan (NCATS), Samarjit Patnaik (NCATS), Hee-Yong Kim (NIAAA). Intellectual Property: HHS Reference No. E-070-2012/0, U.S. Provisional Patent Application 61/624,741 filed April 16, 2012 (expired), International Patent Application PCT/US2013/032333 filed March 15, 2013 (expired), U.S. Patent 9,422,308; German Patent 602013016154.2, French Patent 2847178, and UK Patent 2847178. Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; [email protected]. Dated: October 5, 2017. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development . [FR Doc. 2017-22146 Filed 10-12-17; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47753
SUMMARY: The Food and Drug than 2 business days before the meeting. Dated: October 6, 2017.
Administration (FDA) announces a If FDA is unable to post the background Anna K. Abram,
forthcoming public advisory committee material on its Web site prior to the Deputy Commissioner for Policy, Planning,
meeting of the Orthopaedic and meeting, the background material will Legislation, and Analysis.
Rehabilitation Devices Panel of the be made publicly available at the [FR Doc. 2017–22174 Filed 10–12–17; 8:45 am]
Medical Devices Advisory Committee. location of the advisory committee BILLING CODE 4164–01–P
The general function of the committee is meeting, and the background material
to provide advice and recommendations will be posted on FDA’s Web site after
to the Agency on FDA’s regulatory the meeting. Background material is DEPARTMENT OF HEALTH AND
issues. The meeting will be open to the available at https://www.fda.gov/ HUMAN SERVICES
public. AdvisoryCommittees/Calendar/
DATES: The meeting will be held on default.htm. Scroll down to the National Institutes of Health
December 12, 2017, from 8 a.m. to 6 appropriate advisory committee meeting
p.m. link. Government-Owned Inventions;
Procedure: Interested persons may Availability for Licensing
ADDRESSES: Hilton Washington DC
North/Gaithersburg, salons A, B, C, and present data, information, or views, AGENCY: National Institutes of Health,
D, 620 Perry Pkwy., Gaithersburg, MD orally or in writing, on issues pending HHS.
20877. The hotel’s telephone number is before the committee. Written ACTION: Notice.
301–977–8900. submissions may be made to the contact
FOR FURTHER INFORMATION CONTACT: Sara person on or before December 1, 2017. SUMMARY: The inventions listed below
J. Anderson, Center for Devices and Oral presentations from the public will are owned by an agency of the U.S.
Radiological Health, Food and Drug be scheduled between approximately 1 Government and are available for
Administration, 10903 New Hampshire p.m. and 2 p.m. Those individuals licensing in the U.S.
Ave., Bldg. 66, Rm. G616, Silver Spring, interested in making formal oral FOR FURTHER INFORMATION CONTACT:
MD 20993–0002, 301–796–7047, presentations should notify the contact Licensing information and copies of the
Sara.Anderson@fda.hhs.gov, or FDA person and submit a brief statement of patent applications listed below may be
Advisory Committee Information Line, the general nature of the evidence or obtained by emailing the indicated
1–800–741–8138 (301–443–0572 in the arguments they wish to present, the licensing contact at the National Heart,
Washington, DC area). A notice in the names and addresses of proposed Lung, and Blood, Office of Technology
Federal Register about last minute participants, and an indication of the Transfer and Development Office of
modifications that impact a previously approximate time requested to make Technology Transfer, 31 Center Drive
announced advisory committee meeting their presentation on or before Room 4A29, MSC2479, Bethesda, MD
cannot always be published quickly November 3, 2017. Time allotted for 20892–2479; telephone: 301–402–5579.
enough to provide timely notice. each presentation may be limited. If the A signed Confidential Disclosure
Therefore, you should always check the number of registrants requesting to Agreement may be required to receive
Agency’s Web site at https:// speak is greater than can be reasonably copies of the patent applications.
www.fda.gov/AdvisoryCommittees/ accommodated during the scheduled SUPPLEMENTARY INFORMATION: This
default.htm and scroll down to the open public hearing session, FDA may notice is in accordance with 35 U.S.C.
appropriate advisory committee meeting conduct a lottery to determine the 209 and 37 CFR part 404 to achieve
link, or call the advisory committee speakers for the scheduled open public expeditious commercialization of
information line to learn about possible hearing session. The contact person will results of federally-funded research and
modifications before coming to the notify interested persons regarding their development. Foreign patent
meeting. request to speak by November 9, 2017. applications are filed on selected
SUPPLEMENTARY INFORMATION:
Persons attending FDA’s advisory inventions to extend market coverage
Agenda: On December 12, 2017, the committee meetings are advised that the for companies and may also be available
committee will discuss, make Agency is not responsible for providing for licensing. A description of the
recommendations, and vote on access to electrical outlets. technology follows.
information regarding the premarket FDA welcomes the attendance of the
public at its advisory committee Derivatives of
approval application (PMA) for the
meetings and will make every effort to Docosahexaenoylethanolamide (DEA)
Barricaid Anular Closure Device by
accommodate persons with disabilities. for Neurogenesis
Intrinsic Therapeutics. The proposed
Indication for Use, as stated in the PMA, If you require accommodations due to a The invention pertains to derivatives
is as follows: The Barricaid is intended disability, please contact AnnMarie of docosahexaenoylethanolamide
to be implanted following a limited Williams at Annmarie.Williams@ (synaptamide or DEA) and their use in
discectomy, to prevent reherniation and fda.hhs.gov or 301–796–5966 at least 7 inducing neurogenesis, neurite growth,
the recurrence of pain or dysfunction. days in advance of the meeting. and/or synaptogenesis. As such, these
The Barricaid is indicated for patients FDA is committed to the orderly DEA derivatives can be used as
with radiculopathy (with or without conduct of its advisory committee therapeutics for neurodegenerative
back pain), a posterior or posterolateral meetings. Please visit our Web site at diseases such as traumatic brain injury,
https://www.fda.gov/
asabaliauskas on DSKBBXCHB2PROD with NOTICES
herniation, characterized by spinal cord injury, peripheral nerve
radiographic confirmation of neural AdvisoryCommittees/ injury, stroke, multiple sclerosis,
compression using magnetic resonance AboutAdvisoryCommittees/ autism, Alzheimer’s disease,
imaging, and a large anular defect (e.g., ucm111462.htm for procedures on Huntington’s disease, Parkinson’s
between 4–6 mm tall and between 6–12 public conduct during advisory disease, amyotrophic lateral sclerosis.
mm wide) post discectomy, at one level committee meetings. The DEA derivatives of the invention
between L4 and S1. Notice of this meeting is given under have increased potency and hydrolysis
FDA intends to make background the Federal Advisory Committee Act (5 resistance as compared to native DEA.
material available to the public no later U.S.C. app. 2). Docosahexaenoic acid (DHA), an n-3
VerDate Sep<11>2014 18:05 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1](https://thefederalregister.org/doc/82_FR_47950/page/1.svg)
![47754 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
polyunsaturated fatty acid accumulates property such as patentable material, Improving Smoking Cessation in
in the brain during development, and and personal information concerning Socioeconomically Disadvantaged
has been implicated in learning and individuals associated with the grant Populations via Scalable Interventions.
Date: November 7, 2017.
memory development. DEA, a applications, the disclosure of which Time: 1:00 p.m. to 5:00 p.m.
metabolite derived from DHA, also has would constitute a clearly unwarranted Agenda: To review and evaluate grant
been shown to accelerate neuronal invasion of personal privacy. applications.
growth and development. In vitro Name of Committee: Center for Scientific Place: National Institutes of Health, 6701
studies in which neural progenitor cells Review Special Emphasis Panel; Immune Rockledge Drive, Bethesda, MD 20892
were treated with DEA derivatives System Plasticity in Dental, Oral, and (Telephone Conference Call).
showed an increase in the number of Craniofacial Diseases. Contact Person: Kristen Prentice, Ph.D.,
Date: November 1, 2017. Scientific Review Officer, Center for
somatic neurons produced after Scientific Review, National Institutes of
differentiation. Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant Health, 6701 Rockledge Drive, Room 3112,
Potential Commercial Applications applications. MSC 7808, Bethesda, MD 20892, 301–496–
Place: National Institutes of Health, 6701 0726, prenticekj@mail.nih.gov.
• Neurogenesis, Rockledge Drive, Bethesda, MD 20892 Name of Committee: Center for Scientific
• Neurite growth, (Virtual Meeting). Review Special Emphasis Panel; Small
• Synaptogenesis, Contact Person: Yi-Hsin Liu, Ph.D., Business: Digestive Sciences.
• Therapeutics for traumatic brain Scientific Review Officer, Center for Date: November 8–9, 2017.
injury, spinal cord injury, peripheral Scientific Review, National Institutes of Time: 8:00 a.m. to 5:00 p.m.
nerve injury, stroke, multiple sclerosis, Health, 6701 Rockledge Drive, Room 4214, Agenda: To review and evaluate grant
autism, Alzheimer’s disease, MSC 7814, Bethesda, MD 20892, 301–435– applications.
1781, liuyh@csr.nih.gov. Place: Residence Inn Bethesda, 7335
Huntington’s disease, Parkinson’s Wisconsin Avenue, Bethesda, MD 20814.
disease, and amyotrophic lateral Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–17– Contact Person: Martha Garcia, Ph.D.,
sclerosis. 263: Innovation for HIV Vaccine Discovery. Scientific Reviewer Officer, Center for
Inventors: Erika Englund (NCATS), Date: November 3, 2017. Scientific Review, National Institutes of
Juan Marugan (NCATS), Samarjit Time: 10:00 a.m. to 5:00 p.m. Health, 6701 Rockledge Drive, Room 2186,
Patnaik (NCATS), Hee-Yong Kim Agenda: To review and evaluate grant MSC 7818, Bethesda, MD 20892, 301–435–
(NIAAA). applications. 1243, garciamc@nih.gov.
Intellectual Property: HHS Reference Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific
No. E–070–2012/0, U.S. Provisional Rockledge Drive, Bethesda, MD 20892 Review Special Emphasis Panel; Small
(Virtual Meeting). Business: Computational, Modeling, and
Patent Application 61/624,741 filed Contact Person: Barna Dey, Ph.D., Biodata Management.
April 16, 2012 (expired), International Scientific Review Officer, Center for Date: November 8, 2017.
Patent Application PCT/US2013/032333 Scientific Review, National Institutes of Time: 8:00 a.m. to 6:00 p.m.
filed March 15, 2013 (expired), U.S. Health, 6701 Rockledge Drive, Room 3184, Agenda: To review and evaluate grant
Patent 9,422,308; German Patent Bethesda, MD 20892, 301–451–2796, bdey@ applications.
602013016154.2, French Patent mail.nih.gov. Place: Embassy Suites at the Chevy Chase
2847178, and UK Patent 2847178. Name of Committee: Center for Scientific Pavilion, 4300 Military Road NW.,
Licensing Contact: Michael Review Special Emphasis Panel; Member Washington, DC 20015.
Shmilovich, Esq, CLP; 301–435–5019; Conflict: Epidemiology, Ethical and Contact Person: Allen Richon, Ph.D.,
Population Sciences. Scientific Review Officer, Center for
shmilovm@nih.gov. Scientific Review, National Institutes of
Date: November 3, 2017.
Dated: October 5, 2017. Time: 2:30 p.m. to 4:30 p.m. Health, 6701 Rockledge Drive, Room 6184,
Michael Shmilovich, Agenda: To review and evaluate grant MSC 7892, Bethesda, MD 20892, 301–379–
applications. 9351, allen.richon@nih.hhs.gov.
Senior Licensing and Patenting Manager,
Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific
National Heart, Lung, and Blood Institute,
Rockledge Drive, Bethesda, MD 20892 Review Special Emphasis Panel; Member
Office of Technology Transfer and
(Telephone Conference Call). Conflict: Pathophysiology of
Development .
Contact Person: Gniesha Yvonne Neurodevelopmental Disorders.
[FR Doc. 2017–22146 Filed 10–12–17; 8:45 am] Dinwiddie, Ph.D., Scientific Review Officer, Date: November 8, 2017.
BILLING CODE 4140–01–P Center for Scientific Review, National Time: 11:00 a.m. to 2:00 p.m.
Institutes of Health, 6701 Rockledge Drive, Agenda: To review and evaluate grant
Room 3137, Bethesda, MD 20892, applications.
DEPARTMENT OF HEALTH AND dinwiddiegy@csr.nih.gov. Place: National Institutes of Health, 6701
HUMAN SERVICES Name of Committee: Center for Scientific Rockledge Drive, Bethesda, MD 20892
Review Special Emphasis Panel; PAR Panel: (Telephone Conference Call).
National Institutes of Health Systems Science and Health in the Contact Person: Boris P Sokolov, Ph.D.,
Behavioral and Social Science. Scientific Review Officer, Center for
Center for Scientific Review; Notice of Date: November 7, 2017. Scientific Review, National Institutes of
Closed Meetings Time: 1:00 p.m. to 5:00 p.m. Health, 6701 Rockledge Drive, Room 5217A,
Agenda: To review and evaluate grant MSC 7846, Bethesda, MD 20892, 301–408–
Pursuant to section 10(d) of the applications. 9115, bsokolov@csr.nih.gov.
Federal Advisory Committee Act, as Place: National Institutes of Health, 6701 Name of Committee: Center for Scientific
Rockledge Drive, Bethesda, MD 20892
asabaliauskas on DSKBBXCHB2PROD with NOTICES
amended, notice is hereby given of the Review Special Emphasis Panel; PAR–17–
following meetings. (Telephone Conference Call). 171: Cancer Tissue Engineering Collaborative
Contact Person: Ping Wu, Ph.D., Scientific Research.
The meetings will be closed to the
Review Officer, HDM IRG, Center for Date: November 8, 2017.
public in accordance with the Scientific Review, National Institutes of Time: 12:00 p.m. to 4:30 p.m.
provisions set forth in sections Health, 6701 Rockledge Drive, Room 3166, Agenda: To review and evaluate grant
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Bethesda, MD 20892, 301–451–8428, wup4@ applications.
as amended. The grant applications and csr.nih.gov. Place: National Institutes of Health, 6701
the discussions could disclose Name of Committee: Center for Scientific Rockledge Drive, Bethesda, MD 20892
confidential trade secrets or commercial Review Special Emphasis Panel; PAR Panel: (Virtual Meeting).
VerDate Sep<11>2014 19:23 Oct 12, 2017 Jkt 244001 PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 E:\FR\FM\13OCN1.SGM 13OCN1](https://thefederalregister.org/doc/82_FR_47950/page/2.svg)
Document Created: 2017-10-13 04:33:52
Document Modified: 2017-10-13 04:33:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. | |
| FR Citation | 82 FR 47753 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR